Giacca Mauro, Zacchigna Serena
Molecular Medicine, International Centre for Genetic Engineering and Biotechnology (ICGEB), AREA Science Park, Padriciano 99, 34149 Trieste, Italy.
Cardiovascular Biology Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), AREA Science Park, Padriciano 99, 34149 Trieste, Italy.
J Mol Cell Cardiol. 2015 Dec;89(Pt A):68-74. doi: 10.1016/j.yjmcc.2015.09.017. Epub 2015 Sep 30.
Mounting evidence over the last few years has indicated that the rate of cardiomyocyte proliferation, and thus the extent of cardiac renewal, is under the control of the microRNA network. Several microRNAs (e.g. miR-1) regulate expansion of the cardiomyocyte pool and its terminal differentiation during the embryonic life; some not only promote cardiomyocyte proliferation but also their de-differentiation towards an embryonic cell phenotype (e.g. the miR-302/367 cluster); a few others are involved in the repression of cardiomyocyte proliferation occurring suddenly after birth (e.g. the miR-15 family); others again are not physiologically involved in the regulation of cardiomyocyte turnover, but nevertheless are able to promote cardiomyocyte proliferation and cardiac regeneration when delivered exogenously (e.g. miR-199a-3p). With a few exceptions, the molecular mechanisms underlying the pro-proliferative effect of these microRNAs, most of which appear to act at the level of already differentiated cardiomyocytes, remain to be thoroughly elucidated. The possibility of harnessing the miRNA network to achieve cardiac regeneration paves the way to exciting therapeutic applications. This could be achieved by either administering miRNA mimics or inhibitors, or transducing the heart with viral vectors expressing miRNA-encoding genes.
过去几年越来越多的证据表明,心肌细胞增殖速率以及心脏更新程度受微小RNA网络的调控。几种微小RNA(如miR-1)在胚胎期调控心肌细胞库的扩张及其终末分化;有些微小RNA不仅促进心肌细胞增殖,还能促使其去分化为胚胎细胞表型(如miR-302/367簇);还有一些参与抑制出生后突然发生的心肌细胞增殖(如miR-15家族);另外一些在生理上并不参与心肌细胞更新的调控,但外源性给予时却能够促进心肌细胞增殖和心脏再生(如miR-199a-3p)。除了少数例外情况,这些微小RNA促增殖作用的分子机制大多似乎在已分化的心肌细胞水平发挥作用,仍有待深入阐明。利用微小RNA网络实现心脏再生的可能性为激动人心的治疗应用铺平了道路。这可以通过给予微小RNA模拟物或抑制剂,或者用表达微小RNA编码基因的病毒载体转导心脏来实现。